Patients who achieved a CR and who were MRD-negative following treatment with once-weekly KRd56 vs twice-weekly KRd27
| . | Once-weekly KRd56 (N = 228) . | Twice-weekly KRd27 (N = 226) . | Odds ratio (95% CI) . |
|---|---|---|---|
| No. of patients who were MRD-negative∗ | 49 | 41 | |
| MRD-negative rate, % (95% CI) | 21.5 (16.3-27.4) | 18.1 (13.3-23.8) | 1.235 (0.775-1.970) |
| No. of patients who were MRD-negative at 12 mo† | 43 | 41 | |
| MRD-negative rate, % (95% CI) | 18.9 (14.0-24.6) | 18.1 (13.3-23.8) | 1.060 (0.657-1.711) |
| . | Once-weekly KRd56 (N = 228) . | Twice-weekly KRd27 (N = 226) . | Odds ratio (95% CI) . |
|---|---|---|---|
| No. of patients who were MRD-negative∗ | 49 | 41 | |
| MRD-negative rate, % (95% CI) | 21.5 (16.3-27.4) | 18.1 (13.3-23.8) | 1.235 (0.775-1.970) |
| No. of patients who were MRD-negative at 12 mo† | 43 | 41 | |
| MRD-negative rate, % (95% CI) | 18.9 (14.0-24.6) | 18.1 (13.3-23.8) | 1.060 (0.657-1.711) |
MRD negativity was assessed using next-generation sequencing at a threshold of 10−5 over the duration of the study in the intention-to-treat population.
MRD-negative rate at 12 months was defined as the proportion of patients who achieved MRD negativity at 12 months (±4 weeks) from randomization, as assessed using next-generation sequencing at a threshold of 10−5, in the intention-to-treat population. MRD negativity results from bone marrow samples obtained at 8 to 13 months from randomization and before starting new antimyeloma therapy or disease progression were considered in the calculation.